Type 2 Diabetes Clinical Trial
Official title:
Diabetes Incentive Performance Study(DIPS)at Shanghai Jiading District
Objectives:Physicians from the Shanghai Jiading community clinic were invited to attend the
study seminar. Those physicians who meet the criteria of the study plan were being selected
to participate voluntarily. From their patient's record, the physicians will recruit a total
of 1300 patients with type 2 diabetes who meet the criteria of the Jiading Study.
The study utilizes the social learning theory that motivation and social support are
important to make behavioral change. The mechanism of providing incentive for patients and
physicians will be established after the permission from the Internal Review Board of the
hospital and will be approved by the hospital director. Physicians and their patients were
randomly divided into 4 groups: Group 1- Physicians only; Group 2 - Patients only; Group 3 -
Both Physicians and Patients, Group 4 - control. Groups 1-3 will receive incentives if they
can maintain the ideal level of Hemoglobin A1c (HbA1c) during the 3-years study period. The
forth group serves as a control and will not receive any incentive but will be provided
diabetes education booklet and group education courses for DM control as usual. Based on the
annual evaluation of the level of improvement on HbA1c that is a joint effort of both
patients and physicians to achieve the targeted goal of adequate HBA1c level, the value of
incentives will be increased accordingly. Our ultimate goal is to evaluate the effectiveness
of incentive as an intervention tool to improve the health status of the diabetic patients.
Methods:
This study is an open- label controlled randomized cluster trial and will invite eligible
physicians and their patients to attend the study. These physicians work in health community
center at Shanghai Jiading district and their patients are from the district community. Each
physician should care and monitor at least 20 of his or her patients. This serves as a
cluster randomized unit. The study size consists of 40 or more units within the Jiading
District of Shanghai. Samples will taken from these patients according to the preset
schedule and will measure patients' level of HbA1c accordingly. The physicians will recruit
their patients who meet the criterion of the Jiading Study Standard. All of these patients
have established their own health record by physicians in the community health center. To
the enrolled patients, the study will obtain the information such as demographic
characteristics, diagnosis and treatment, complications , various of biochemical index,
skill and capacity of disease self-management, etc. Biomarkers and genetic risk factors will
be evaluated in the study subjects. The study also will give several training courses to the
enrolled physicians and the patients, all of them need to meet the study criteria and will
sign the inform consent to participate in the study.
The study will use the method of randomized complete block design to classify the enrolled
units into 4 groups. Group 1- Physicians only; Group 2 - Patients only; Group 3 - Both
Physicians and Patients, Group 4 - control. Groups 1-3 will receive incentives if they can
obtain or/and maintain the ideal level of Hemoglobin A1c (HbA1c) during the 3-years study
period. We aim to achieve a target of HbA1c < 7% or to reduce 0.5% HbA1c level annually
during 3 years study period. The incentive is in the form of cash or same value awards. The
amount of the incentives will increase annually depending upon the change of HbA1c. The
award is served as an motivation factor and token for rewarding the desire for
self-discipline and disease management to enhance self-efficacy. The control group will not
receive any incentives but will be provided diabetes education booklet and group education
courses for DM control as usual.
The study will use the existing tele-medicine system to monitor patients' blood pressure and
blood glucose remotely. The system of the telemedicine will also provide a series of
diabetes education and training courses to support the physicians and the patients about the
diabetes treatment, care and the self-management on the diseases. The study will document
the changes on the patients' blood pressure, biochemical index, medication, quality of life,
self-management skill of diabetes, life behavior, complications and costs.
Endpoint of the study:
The study will be ended in 36 months, endpoint measurement indicators are listed below:
1. Withdraw rate: Patient who drop out from the study;
2. Diabetic complication rate: Patient with new complications, such as macro- or
micro-vascular complications;
3. Admission rate due to diabetic related illness: Patient's diabetic condition worsen,
needs to be hospitalized or surgery;
4. Frequency of hypoglycemia incidences:Patient who has frequently severe hypoglycemia or
other complications that can not continue the study;
5. Mortality rate among enrolled patients Death.
;
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05219994 -
Targeting the Carotid Bodies to Reduce Disease Risk Along the Diabetes Continuum
|
N/A | |
Completed |
NCT04056208 -
Pistachios Blood Sugar Control, Heart and Gut Health
|
Phase 2 | |
Completed |
NCT02284893 -
Study to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin in Combination With Metformin Compared to Sitagliptin in Combination With Metformin in Adult Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Therapy Alone
|
Phase 3 | |
Completed |
NCT04274660 -
Evaluation of Diabetes and WELLbeing Programme
|
N/A | |
Active, not recruiting |
NCT05887817 -
Effects of Finerenone on Vascular Stiffness and Cardiorenal Biomarkers in T2D and CKD (FIVE-STAR)
|
Phase 4 | |
Active, not recruiting |
NCT05566847 -
Overcoming Therapeutic Inertia Among Adults Recently Diagnosed With Type 2 Diabetes
|
N/A | |
Recruiting |
NCT06007404 -
Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
|
||
Completed |
NCT04965506 -
A Study of IBI362 in Chinese Patients With Type 2 Diabetes
|
Phase 2 | |
Recruiting |
NCT06115265 -
Ketogenic Diet and Diabetes Demonstration Project
|
N/A | |
Active, not recruiting |
NCT03982381 -
SGLT2 Inhibitor or Metformin as Standard Treatment of Early Stage Type 2 Diabetes
|
Phase 4 | |
Completed |
NCT04971317 -
The Influence of Simple, Low-Cost Chemistry Intervention Videos: A Randomized Trial of Children's Preferences for Sugar-Sweetened Beverages
|
N/A | |
Completed |
NCT04496154 -
Omega-3 to Reduce Diabetes Risk in Subjects With High Number of Particles That Carry "Bad Cholesterol" in the Blood
|
N/A | |
Completed |
NCT04023539 -
Effect of Cinnamomum Zeylanicum on Glycemic Levels of Adult Patients With Type 2 Diabetes
|
N/A | |
Recruiting |
NCT05572814 -
Transform: Teaching, Technology, and Teams
|
N/A | |
Enrolling by invitation |
NCT05530356 -
Renal Hemodynamics, Energetics and Insulin Resistance: A Follow-up Study
|
||
Completed |
NCT04097600 -
A Research Study Comparing Active Drug in the Blood in Healthy Participants Following Dosing of the Current and a New Formulation (D) Semaglutide Tablets
|
Phase 1 | |
Completed |
NCT03960424 -
Diabetes Management Program for Hispanic/Latino
|
N/A | |
Completed |
NCT05378282 -
Identification of Diabetic Nephropathy Biomarkers Through Transcriptomics
|
||
Active, not recruiting |
NCT06010004 -
A Long-term Safety Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes
|
Phase 3 | |
Completed |
NCT03653091 -
Safety & Effectiveness of Duodenal Mucosal Resurfacing (DMR) Using the Revita™ System in Treatment of Type 2 Diabetes
|
N/A |